Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 7/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248113 | 0.85 | PNMT (0.38) | CHRNB2CHRNA4PNMTCD44MAOB | |
| SCHEMBL22923562 | 0.82 | DRD2 (0.33) | — | |
| SCHEMBL19711547 | 0.77 | CHRNB2 (0.41) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL19667229 | 0.77 | PNMT (0.44) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL30207837 | 0.77 | PNMT (0.48) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL19678853 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL19667407 | 0.77 | PNMT (0.48) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL25281145 | 0.74 | PNMT (0.46) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| SCHEMBL30183105 | 0.74 | PNMT (0.46) | CHRNB2CHRNA4PNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL31186539 | 0.73 | PNMT (0.45) | CHRNB2CHRNA4PNMTADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | CHRNB2 4426/4885CHRNA4 4526/4885PNMT 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.